Phytotherapy in urology. current scientific evidence of its application in benign prostatic hyperplasia and prostate adenocarcinoma;Fitoterapia en Urología. Evidencia científica actual de su aplicación en hiperplasia benigna de próstata y adenocarcinoma de próstata

Actas Urologicas Espanolas

Volumn 37, Issue 2, 2013, Pages 114-119

  Moran E ^a   Budia A ^a   Broseta, E ^a   Boronat, F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Benign prostate hyperplasia; Phytotherapy; Prostatic adenocarcinoma

Indexed keywords

ADENOCARCINOMA; ARTICLE; HUMAN; MALE; PHYTOTHERAPY; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84874666921     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2012.07.005     Document Type: Short Survey

References (40)

1. J. Castiñeiras Fernández, J.M. Cozar Olmo, A. Fernández-Pro, J.A. Martín, F.J. Brenes Bermúdez, and E. Naval Pulido Criterios de referencia de la HBP en antención primaria. Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología Actas Urol Esp 34 2010 24 34
2. R. Vela Navarrete, J.V. Garcia Cardoso, A. Barat, F. Manzarbeitia, and A. López Farré BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay Eur Urol 44 2003 549 555 (Pubitemid 37328630)
3. P. Pais Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II Adv Ther 8 2010 555 563
4. S. Bent, C. Kane, K. Shinohara, J. Neuhaus, E.S. Hudes, and H. Goldberg Saw palmetto for benign prostatic hyperplasia N Engl J Med 354 2006 557 566 (Pubitemid 43209103)
5. R. Shi, Q. Xie, X. Gang, J. Lun, L. Cheng, and A. Pantuck Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China J Urol 179 2008 610 615
6. B. Djavan, Y.K. Fong, A. Chaudry, A. Reissigl, T. Anagnostou, and F. Bagheri Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting World J Urol 23 2005 253 256
7. F. Debruyne, G. Koch, P. Boyle, F.C. Da Silva, J.G. Gillenwater, and F.C. Hamdy Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study Eur Urol 41 2002 497 506
8. F. Debruyne, P. Boyle, F. Calais Da Silva, J.G. Gillenwater, F.C. Hamdy, and P. Perrin Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis Eur Urol 45 2004 773 779
9. J. Carballido, J.L. Ruiz-Cerdá, M. Unda, V. Baena, P. Campoy, and J. Manasanch Estudio económico del tratamiento de la HBP en la atención medica especializada en España. Estudio coste-beneficio de dos medicamentos frecuentemente usados en su tratamiento Actas Urol Esp 32 2008 916 925
10. G.S. Gerber, D. Kuznetsov, B.C. Johnson, and J.D. Burstein Randomized, doubleblind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms Urology 58 2001 960 965
11. R. Anceschi, M. Bisi, N. Ghidini, G. Ferrari, and P. Ferrari Serenoa repens (Permixon(R)) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia Minerva Urol Nefrol 62 2010 219 223
12. A. Tuncel, K. Ener, O. Han, V. Nalcacioglu, O. Aydin, and S. Seckin Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate Scand J Urol Nephrol 43 2009 377 382
13. M.T. Quiles, M.A. Arbós, A. Fraga, I.M. de Torres, J. Reventós, and J. Morote Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH) Prostate 70 2010 1044 1053
14. A. Ishani, R. MacDonald, D. Nelson, I. Rutks, and T.J. Wilt Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis Am J Med 109 2000 654 664
15. S. Madersbacher, M. Marszalek, J. Lackner, P. Berger, and G. Schatzl The long-term outcome of medical therapy for BPH Eur Urol 51 2007 1522 1533 (Pubitemid 46634774)
16. A. Hutchison, R. Farmer, K. Verhamme, R. Berges, and R.V. Navarrete The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries Eur Urol 51 2007 207 215
17. B. Djavan Treatment of symptomatic benign prostatic hyperplasia: current and future clinical practice in Europe -What is really happening? Eur Urol 6 2007 446 453 (Pubitemid 46216187)
18. M. Unda Urzaiz, F. Rodríguez Alcántara, X. Badia, M. García Losa, J. Carballido Rodríguez, and R. Dal-Ré Saavedra Características sociosanitarias y diagnósticas del paciente prostático en España a finales del siglo xx Actas Urol Esp 25 2001 200 206
19. V. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I.A. Siddiqui, and D.N. Syed Combined inhibitory effects of greentea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo Clin Cancer Res 13 2007 1611 1619 (Pubitemid 46450454)
20. M. Brausi, F. Rizzi, and S. Bettuzzi Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update Eur Urol 54 2008 472 473
21. N. Kikuchi, K. Ohmori, T. Shimazu, N. Nakaya, S. Kuriyama, and Y. Nishino No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study Br J Cancer 95 2006 371 373 (Pubitemid 44187600)
22. S. McCarthy, A. Caporali, S. Enkemann, M. Scaltriti, S. Eschrich, and P. Davalli Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer Mol Oncol 1 2007 196 204 (Pubitemid 47199136)
23. H.D. Sesso, R.S. Paffenbarger Jr., and I.M. Lee Alcohol consumption and risk of prostate cancer: the Harvard Alumni Health Study Int J Epidemiol 30 2001 749 755 (Pubitemid 32827379)
24. D. Benítez, E. Pozo-Guisado, A. Alvarez-Barrientos, P. Fernandez-Salguero, and E. Castello Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines J Androl 28 2007 282 293 (Pubitemid 46423911)
25. M. Athar, J. Back, X. Tang, K. Kim, L. Kopelovich, and D. Bickers Resveratrol: a review of pre-clinical studies for human cancer prevention Toxicol Appl Pharmacol 224 2007 274 283 (Pubitemid 47575677)
26. C.M. Velicer, A. Kristal, and E. White Alcohol use and the risk of prostate cancer: results from the VITAL cohorte study Nutr Cancer 56 2006 50 56 (Pubitemid 46173413)
27. C. Chao, R. Haque, S.K. Van Den Eeden, B.J. Caan, K.Y. Poon, and V.P. Quinn Red wine consumption and risk of prostate cancer: the California men's health study Int J Cancer 126 2009 171 179
28. A. Benedetti, M.E. Parent, and J. Siemiatycki Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal Cancer Detect Prev 32 2009 352 362
29. E.J. Kim, H. Park, S.Y. Park, J.G. Jun, and J.H. Park The grape component piceatannol induces apoptosis in DU145 human prostate cancer cells via the activation of extrinsic and intrinsic pathways J Med Food 12 2009 943 951
30. I. Romero, A. Ferruelo, and A. Berenguer Dieta y cáncer de próstata Actas Urol Esp 27 2003 399 409
31. R.A. Jarred, M. Keikha, C. Dowling, S.J. McPherson, A.M. Clare, and A.J. Husband Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones Cancer Epidemiol Biomarkers Prev 11 2002 1689 1696 (Pubitemid 36020026)
32. N. Gray, X. Liu, R. Choi, M. Blackman, and J. Arnold Endocrine-ommune- paracrine interactions in prostate cells: a model for mechanistic studies of phytomedicines Cancer Prev Res 2 2009 134 142
33. J.M. Holzbeierlein, J. McIntosh, and J.B. Thrasher The role of soy phytoestrogens in prostate cancer Curr Opin Urol 15 2005 17 22 (Pubitemid 40105520)
34. N.B. Kumar, A. Cantor, K. Allen, D. Riccardi, K. Besterman-Dahan, and J. Seigne The specific role of isoflavones in reducing prostate cancer risk Prostate 59 2004 141 147 (Pubitemid 38481225)
35. K.F. Adams, C. Chen, K.M. Newton, J.D. Potter, and J.W. Lampe Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial Cancer Epidemiol Biomarkers Prev 13 2004 644 648 (Pubitemid 38737902)
36. N. Kurahashi, M. Iwasaki, S. Sasazuki, T. Otani, M. Inoue, and S. Tsugane Soy product and isoflavone consumption in relation to prostate cancer in Japanese men Cancer Epidemiol Biomarkers Prev 16 2007 538 545 (Pubitemid 46548658)
37. S. Basak, D. Pookot, E. Noonan, and R. Dahiya Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function Mol Cancer Ther 7 2008 3195 3202
38. L. Yan, and E.L. Spitznagel Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis Am J Clin Nutr 89 2009 1155 1163
39. J.M. Pendleton, W.W. Tan, S. Anai, M. Chang, W. Hou, and K.T. Shiverick Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy BMC Cancer 8 2008 132
40. V. Gupta, H. Zhang, S. Banerjee, D. Kong, J. Raffoul, and H. Fazlul Radiation-induced HIF-1α cell survival pathway is inhibited by soy isoflavones in prostate cancer cells Int J Cancer 124 2009 1675 1684